Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Refixia

- PMLiVE

Novo Nordisk’s Xultophy diabetes combo approved in Europe

Once-daily injection combines the firm's Tresiba and Victoza

- PMLiVE

FDA panel backs Novo Nordisk’s liraglutide for obesity

Committee says diabetes drug could be used to reduce weight

- PMLiVE

Liraglutide seems effective in obesity, says FDA reviewer

Novo Nordisk drug is already successful diabetes treatment

- PMLiVE

Novo Nordisk gives up on inflammation R&D

Follows disappointing trial results for arthritis drug

- PMLiVE

Novo Nordisk debuts diabetes combo in Mexico

Requires fewer daily injections than current insulin treatment

- PMLiVE

Team Novo Nordisk to compete in The Tour of Britain

World’s first all-diabetes pro-cycling team will cycle over 1,300km in eight days

- PMLiVE

Novo launches diabetes campaign in Copenhagen

Follows introduction of ‘Cities Changing Diabetes’ programme in Mexico

- PMLiVE

Baxter ‘will file long-acting haemophilia drug by year-end’

New version of Advate clears late-stage trial

- PMLiVE

Baxter opens Advate facility in Singapore

Follows EU approval for haemophilia A drug plant

- PMLiVE

Two blood cancer drugs among CHMP recommendations

Five new drugs, including Janssen’s Imbruvica and Gilead’s Zydelig, backed for use in Europe

- PMLiVE

ADA: Novo says switching to Tresiba could reduce NHS costs

Real world data backs insulin’s ability to reduce hypoglycaemia in people with diabetes

- PMLiVE

Haemophilia Society launches UK awareness drive

Charity tackles poor understanding of bleeding disorder

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links